Daniel D. Shoemaker
2019
In 2019, Daniel D. Shoemaker earned a total compensation of $2.8M as Chief Scientific Officer at Fate Therapeutics, a 111% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $150,938 |
|---|---|
| Option Awards | $1,547,898 |
| Salary | $375,000 |
| Stock Awards | $744,750 |
| Total | $2,818,586 |
Shoemaker received $1.5M in option awards, accounting for 55% of the total pay in 2019.
Shoemaker also received $150.9K in non-equity incentive plan, $375K in salary and $744.8K in stock awards.
Rankings
In 2019, Daniel D. Shoemaker's compensation ranked 4,342nd out of 13,971 executives tracked by ExecPay. In other words, Shoemaker earned more than 68.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,342 out of 13,971 | 69th |
Division Manufacturing | 1,597 out of 5,695 | 72nd |
Major group Chemicals And Allied Products | 558 out of 2,194 | 75th |
Industry group Drugs | 470 out of 1,880 | 75th |
Industry Biological Products, Except Diagnostic Substances | 103 out of 389 | 74th |
Source: SEC filing on April 21, 2021.
Shoemaker's colleagues
We found three more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2019.